SF
AKBA icon

Synovus Financial’s Akebia Therapeutics AKBA Stock Holding History

Synovus Financial’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-233
Closed -$3K – 720
2020
Q2 		$3K Hold
233
– – ﹤0.01% 1376
2020
Q1 		$2K Hold
233
– – ﹤0.01% 1912
2019
Q4 		$1K Hold
233
– – ﹤0.01% 1462
2019
Q3 		$1K Hold
233
– – ﹤0.01% 1410
2019
Q2 		$1K Hold
233
– – ﹤0.01% 1336
2019
Q1 		$2K Hold
233
– – ﹤0.01% 1331
2018
Q4 		$1K Hold
233
– – ﹤0.01% 1346
2018
Q3 		$2K Buy
+233
New +$2.08K ﹤0.01% 1320

Other funds holding AKBA

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Synovus Financial's AKBA Position: Q3 2020 in Review

Synovus Financial sold out of Akebia Therapeutics (AKBA) in Q3 2020, closing a stake of 233 shares — an estimated $3K sold.

Synovus Financial first reported a position in AKBA in Q3 2018 and held it in 8 quarters. The position peaked at $3K in Q2 2020. 164 funds tracked by Wall St. Rank hold AKBA as of Q3 2020.

  • Synovus Financial reported no remaining Akebia Therapeutics position as of Q3 2020 after selling out during the quarter.
  • Synovus Financial sold 233 Akebia Therapeutics shares in Q3 2020, an estimated $3K.
  • Synovus Financial first reported a position in Akebia Therapeutics in Q3 2018 and held it in 8 quarters.
  • Synovus Financial's Akebia Therapeutics position peaked at $3K in Q2 2020.
  • 164 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q3 2020.

Based on Synovus Financial's 13F filing for Q3 2020, filed 9 Nov 2020.